ReviewSignal transduction and targeted therapy2020
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.
Review in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Cancer biology & medicine · 2023Guideline
- Dose fractionation of CAR-T cells. A systematic review of clinical outcomes.Journal of experimental & clinical cancer research : CR · 2023Pooled it
- Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.Nature communications · 2026Trial
- Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.Leukemia · 2022Trial
- Cardiotoxicity of T cell immunotherapies.Nature reviews. Cardiology · 2026Review
- Morphologic and immunophenotypic characterization of lymphocytosis following BCMA-targeted CAR-T cell therapy in relapsed/refractory multiple myeloma.Haematologica · 2026Article
- Organ-specific local cytokine release syndrome after anti-CD19 CAR-T therapy with salivary gland involvement: a case report, literature review, and a diagnostic alert for tocilizumab-associated cervical swelling.Annals of hematology · 2026Review
- Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial.Nature cancer · 2026Article
- Biomarker-empowered precision navigation of CAR-T cell therapy.Molecular cancer · 2026Review
- Teclistamab-Induced Localized Pleural Cavity Cytokine Release Syndrome in a Multiple Myeloma Patient Managed with Intrapleural Dexamethasone Administration.Journal of blood medicine · 2026Article
- iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.Frontiers in immunology · 2026Review
- Spatio-temporal kinetics of patients' CAR-T cells in blood and serous cavity effusion: real-world clinical insights.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia.Nature biomedical engineering · 2025Article
- Prognostic implications of adverse events associated with CAR-T cell therapy: a population-based global observational study.EClinicalMedicine · 2025Article
- B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome.bioRxiv : the preprint server for biology · 2025Article
- Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors.Journal for immunotherapy of cancer · 2025Article
- Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma.Blood advances · 2025Observational
- CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.PLoS computational biology · 2025Article
- Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions.EBioMedicine · 2025Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T (CAR T) cell therapy has demonstrated efficacy in the treatment of haematologic malignancies. However, the accompanying adverse events, the most common of which is cytokine release syndrome (CRS), substantially limit its wide application. Due to its unique physiological characteristics, CRS in CAR T-cell treatment for B-cell non-Hodgkin lymphoma (B-NHL) may exhibit some special features. Although existing guidelines had greatly promoted the recognition and management of CRS, many recommendations are not fully applicable to B-NHL. Therefore, it is imperative to identify responses that are specific to CRS observed following CAR T treatment for B-NHL. Based on underlying biological processes and known pathophysiological mechanisms, we tentatively propose a new model to illustrate the occurrence and evolution of CAR T-cell-therapy-related CRS in B-NHL. In this model, tumour burden and bone marrow suppression are considered determinants of CRS. Novel phenomena after CAR T-cell infusion (such as local inflammatory response) are further identified. The proposed model will help us better understand the basic biology of CRS and recognize and manage it more rationally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.